MiniMed posts fiscal Q1 2027 revenue growth of 17% amid U.S. expansion
MiniMed delivered strong Q1 2027 results with net sales of $843 million, aided by U.S. acceleration and robust international growth. The company raised fiscal year organic revenue guidance and highlighted key FDA submissions and product launches.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day